Schedule 13G ownership disclosure

Aligos Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 01626L204

Event date: 2025-03-31

Filing-level shares
315,383.00
Percent of class
5.2%
  • Woodline Partners LP

    Shares: 315,383.00 · Class: 5.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-25-002357
Form type
SCHEDULE 13G
Filer
Aligos Therapeutics, Inc.
CIK
CIK 1799448
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub